CSIMarket Company Name, Ticker, Industry, else..
 
Metagenomi Therapeutics Inc   (NASDAQ: MGX)
 
Price: $1.1800 $-0.01 -0.840%
Day's High: $1.1899000406265259 Week Perf: -2.48 %
Day's Low: $ 1.17 30 Day Perf: -0.84 %
Volume (M): 106,855 52 Wk High: $ 3.95
Volume (M$): $ 0 52 Wk Avg: $1.64
Open: $1.18 52 Wk Low: $1.13



 Market Capitalization (Millions $) 44
 Shares Outstanding (Millions) 38
 Employees 119
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -93
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company conducts research and development programs centered on genome editing technology and platforms. It advances product candidates through preclinical studies and clinical trials, utilizing its technology to develop a pipeline of therapeutic programs.


   Company Address: 5959 Horton Street Emeryville 94608 CA
   Company Phone Number: 871-4880   Stock Exchange / Ticker: NASDAQ MGX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Advanced Precision in Genome Editing Metagenomi’s MGX-001 Nuclease Demonstrates Unparalleled Specificity at RNA Con...

Published Wed, Dec 11 2024 11:30 PM UTC

The advancement of genome editing tools has transformed the landscape of genetic engineering. At the recent Nature Conference RNA at the Bench and Bedside IV, Metagenomi introduced MGX-001, a cutting-edge gene editing solution utilizing the innovative MG29-1 nuclease. This article delves into the specificity and efficiency of this novel genome editing tool, highlighting i...
Clinical Study

Sustaining Hope Metagenomis Innovative Approach to Hemophilia A Gene Therapy Surges Forward,

Published Tue, Dec 10 2024 2:17 AM UTC

Harnessing Genetic Innovation: Metagenomi s Promising Breakthrough in Hemophilia A Therapy Showcased at ASH 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow-up In an inspiring leap forward for genetic medicine and hemophilia management, Metagenomi ...
Announcement

Investors Rally Metagenomi, Inc. Faces Class Action Amid Significant Losses

Published Thu, Nov 21 2024 6:20 PM UTC

In the dynamic landscape of biotechnology and drug discovery, the fortunes of companies can shift dramatically, leading to significant implications for investors. A recent wave of legal actions has emerged surrounding Metagenomi, Inc. (NASDAQ: MGX), a company that has captured attention in the sector but is now facing scrutiny due to investor losses.Levi & Korsinsky, LLP, a ...
Clinical Study

Metagenomi to Showcase Preclinical Data on Gene Editing for Hemophilia A at ASH Annual Meeting,

Published Tue, Nov 5 2024 9:05 PM UTC

: Metagenomi, Inc. has announced that their latest preclinical data regarding hemophilia A, specifically the site-specific insertion of the Factor VIII gene, will be presented at the upcoming American Society of Hematology (ASH) 66th Annual Meeting. This development, highlighting sustainable Factor VIII expression in nonhuman primates, may advance therapeutic options for ind...
Management Announcement

Navigating the Turbulent Waters of Biotech: Metagenomi’s Fight for Redemption Amid Legal Troubles

Published Tue, Oct 15 2024 12:58 AM UTC

Metagenomi Inc. (NASDAQ: MGX), a rising player in the rapidly evolving biotechnology landscape, finds itself at a crossroads. As the company unveils its groundbreaking SMART Editing Platform at the AIChE 7th International Conference on CRISPR Technologies, it simultaneously grapples with severe financial losses and a mounting legal crisis that threatens to overshadow its sci...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.28
Price to Sales (Expected) -
Price to Book 0.39
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.37
Working Capital Ratio 4.54
Leverage Ratio (MRQ) 0.54
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.49 $
Revenues (TTM) 0.36 $
Cash Flow (TTM) -
Cash 3.21 $
Book Value 2.99 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -785,395
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.